Phenytoin/isradipine interaction causing severe neurologic toxicity.
OBJECTIVE
To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction.


METHODS
A 21-year-old white man, with propionic acidemia and seizures treated with phenytoin and carbamazepine, was started on isradipine for essential hypertension. Soon thereafter, he developed acute and severe lethargy, ataxia, dysarthria, and weakness that resolved once isradipine was withheld. Phenytoin concentrations were within normal limits or elevated, despite sequential reductions of phenytoin dosage, during concomitant isradipine administration.


CONCLUSIONS
Isradipine is a known inhibitor of the CYP450 isoenzyme family. Although the daily dose of phenytoin was decreased significantly, phenytoin blood concentrations remained high, suggesting a pharmacokinetic interaction. Previously, the patient had never had neurologic symptoms associated with increased phenytoin concentrations. This also indicates a likely pharmacodynamic interaction between phenytoin and the calcium-channel blocker. Both phenytoin and isradipine have been shown to bind to calcium channels and to inhibit calcium entry into the cells. Binding of isradipine to the brain has been described in humans and animals, and calcium-channel blockers have been shown to cause potentiation of anticonvulsant action of phenytoin.


CONCLUSIONS
Acute pharmacokinetic and pharmacodynamic interactions between phenytoin and isradipine were probably responsible for the lethargy, dysarthria, ataxia, and weakness our patient developed. The combination of phenytoin and calcium-channel blockers should be used with caution.
Cachat
Francois
F
Division of Pediatric Nephrology, University of Virginia, Charlottesville, VA 22908, USA.
Tufro
Alda
A
D000138:Acidosis / Q000150:complications / Q000188:drug therapy; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000009:adverse effects* / Q000627:therapeutic use; D004347:Drug Interactions; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D017275:Isradipine / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D020258:Neurotoxicity Syndromes / Q000523:psychology*; D010672:Phenytoin / Q000009:adverse effects*; D011605:Psychoses, Substance-Induced / Q000523:psychology*; D012640:Seizures / Q000150:complications / Q000188:drug therapy
D000927:Anticonvulsants; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D010672:Phenytoin; D017275:Isradipine